Overview

Study Evaluating Venlafaxine Extended-Release in Depressed and Anxious Patients

Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
To examine the efficacy and safety of venlafaxine XR in the treatment of physical and emotional symptoms in patients with an operationally-defined diagnosis of multisomatoform disorder (MSD).
Phase:
Phase 4
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Venlafaxine Hydrochloride